中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 38 Issue 4
Apr.  2022
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(4): 908-912

Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2022.04.034
  • 1.

    Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

  • 2.

    Department of Infectious Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China

  • 3.

    Department of Infectious Diseases, Peking University International Hospital, Beijing 100034, China

Research funding:

Yunnan Province High-level Health Talent Project (H-2017071);

Yunnan Provincial Department of Education Research Fund (2021J0239)

More Information
    Abstract
  • Autoimmune hepatitis (AIH) is an inflammatory disease of the liver mediated by autoimmune response, and in the diagnosis and treatment of AIH, it is of great importance to accurately assess the progression of liver inflammation, screen out the patients requiring corticosteroid therapy, and evaluate the therapeutic outcome. This article introduces a variety of new noninvasive techniques which have been discovered by clinical and experimental studies in recent years and have the potential to evaluate the progression of AIH, as well as the advantages and disadvantages of each technique. It is concluded that the new noninvasive techniques have more advantages in guiding the corticosteroid therapy for AIH, but further clinical studies are still needed for verification.

     

    • FullText(HTML)

  • 肝细胞癌（HCC）是临床常见的恶性肿瘤之一。HCC早期治疗以手术切除为主，但侵袭性HCC的治疗策略目前选择有限，索拉非尼、仑伐替尼及程序性细胞死亡受体1及其配体免疫抑制剂治疗HCC的效果不佳，临床有效率不足30%。因此，亟需进一步探究HCC的发病机制与治疗靶点。随着基因组学研究的发展，对HCC肿瘤生物学的认识逐渐深入，但HCC的泛素化特征尚不明晰。本研究旨在揭示HCC的泛素化特征，并探寻可指导侵袭性HCC临床诊断和治疗的潜在生物标志物。

    陆军军医大学第一附属医院（重庆西南医院）谢传明教授、张雷达教授与重庆医科大学侯宇教授等通过对85例HCC患者肿瘤及相邻正常肝组织进行蛋白质组学、磷酸化修饰组学和泛素化修饰组学测序与分析发现，COL4A1、LAMC1和LAMA4在无病生存期较差患者中高表达。磷酸化与泛素化修饰在代谢和转移相关信号通路中存在关联。利用泛素化组学和蛋白质组学数据对HCC进行分子分型，发现具有不同临床特征的3个亚型：S-‍Ⅰ、S-‍Ⅱ和S-Ⅲ。S-‍Ⅰ亚型以代谢相关蛋白高表达为特征，预后最好；S-Ⅲ亚型与增殖/转移信号通路密切相关，预后最差，表现为总生存期最短和复发率最高；而S-‍Ⅱ亚型则介于两者之间。研究发现，生物标志物TUBA1A、BHMT2、BHMT和ACY1的表达表现出不同的泛素化水平，与HCC患者预后不良密切相关，表明靶向这些蛋白质或其泛素化修饰蛋白可能对临床治疗有益。此外，研究证实TUBA1A K370去泛素化可驱动HCC发生与转移，这主要归因于AKT介导的USP14激活。TUBA1A K370去泛素化标志着一类高侵袭性HCC亚型。值得注意的是，靶向AKT-USP14-TUBA1A复合物可促进TUBA1A降解，并在体内阻断HCC发生。

    总之，本研究从泛素化组学、磷酸化组学和蛋白质组学角度对HCC进行了全面的整合分析，该研究不仅加深了对HCC中泛素化特征的了解，并为开发新的HCC生物标志物和潜在的治疗靶点提供了依据。

    摘译自LIN XT, LUO YD, MAO C, et al. Integrated ubiquitomics characterization of hepatocellular carcinomas[J]. Hepatology, 2024. DOI: 10.1097/HEP.0000000000001096. [Online ahead of print]

    (陆军军医大学第一附属医院肝胆外科 谢传明 报道）

    • References(40)
  • [1]
    GRØNBÆK L, VILSTRUP H, JEPSEN P. Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study[J]. J Hepatol, 2014, 60(3): 612-617. DOI: 10.1016/j.jhep.2013.10.020.
    [2]
    BISCHOFF S, YESMEMBETOV K, ANTONI C, et al. Autoimmune Hepatitis: A review of established and evolving treatments[J]. J Gastrointestin Liver Dis, 2020, 29(3): 429-443. DOI: 10.15403/jgld-2667.
    [3]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004. DOI: 10.1016/j.jhep.2015.06.030.
    [4]
    MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
    [5]
    WANG G, TANAKA A, ZHAO H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: The diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257. DOI: 10.1007/s12072-021-10170-1.
    [6]
    YEOMAN AD, WESTBROOK RH, ZEN Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis[J]. Hepatology, 2011, 53(3): 926-934. DOI: 10.1002/hep.24141.
    [7]
    van GERVEN NM, VERWER BJ, WITTE BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission[J]. J Hepatol, 2013, 58(1): 141-147. DOI: 10.1016/j.jhep.2012.09.009.
    [8]
    DIESTELHORST J, JUNGE N, JONIGK D, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep, 2018, 8(1): 419. DOI: 10.1038/s41598-017-18818-5.
    [9]
    ROUAS R, FAYYAD-KAZAN H, EL ZEIN N, et al. Human natural Treg microRNA signature: Role of microRNA-31 and microRNA-21 in FOXP3 expression[J]. Eur J Immunol, 2009, 39(6): 1608-1618. DOI: 10.1002/eji.200838509.
    [10]
    LIU Y, CHEN H, HAO J, et al. Characterization and functional prediction of the microRNAs differentially expressed in a mouse model of concanavalin A-induced autoimmune hepatitis[J]. Int J Med Sci, 2020, 17(15): 2312-2327. DOI: 10.7150/ijms.47766.
    [11]
    TU H, CHEN D, CAI C, et al. MicroRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation[J]. J Cell Mol Med, 2020, 24(2): 1256-1267. DOI: 10.1111/jcmm.14750.
    [12]
    MIGITA K, KOMORI A, KOZURU H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis[J]. PLoS One, 2015, 10(11): e0136908. DOI: 10.1371/journal.pone.0136908.
    [13]
    CZAJA AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 547-564. DOI: 10.1080/17474124.2018.1453356.
    [14]
    KUNO A, IKEHARA Y, TANAKA Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis[J]. Sci Rep, 2013, 3: 1065. DOI: 10.1038/srep01065.
    [15]
    URA K, FURUSYO N, OGAWA E, et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C[J]. Aliment Pharmacol Ther, 2016, 43(1): 114-124. DOI: 10.1111/apt.13431.
    [16]
    UMEMURA T, JOSHITA S, SEKIGUCHI T, et al. Serum wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol, 2015, 110(6): 857-864. DOI: 10.1038/ajg.2015.118.
    [17]
    NISHIKAWA H, ENOMOTO H, IWATA Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis[J]. Hepatol Res, 2016, 46(7): 613-621. DOI: 10.1111/hepr.12596.
    [18]
    BONGARZONE S, SAVICKAS V, LUZI F, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A medicinal chemistry perspective[J]. J Med Chem, 2017, 60(17): 7213-7232. DOI: 10.1021/acs.jmedchem.7b00058.
    [19]
    HUDSON BI, LIPPMAN ME. Targeting RAGE signaling in inflammatory disease[J]. Annu Rev Med, 2018, 69: 349-364. DOI: 10.1146/annurev-med-041316-085215.
    [20]
    WU R, LIU Y, YAN R, et al. Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis[J]. J Transl Med, 2020, 18(1): 384. DOI: 10.1186/s12967-020-02556-w.
    [21]
    CHEN YY, JEFFERY HC, HUNTER S, et al. Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis[J]. Hepatology, 2016, 64(1): 138-150. DOI: 10.1002/hep.28517.
    [22]
    HUANG H, DENG Z. Adoptive transfer of regulatory T cells stimulated by Allogeneic Hepatic Stellate Cells mitigates liver injury in mice with concanavalin A-induced autoimmune hepatitis[J]. Biochem Biophys Res Commun, 2019, 512(1): 14-21. DOI: 10.1016/j.bbrc.2019.02.147.
    [23]
    MATAKI N, KIKUCHI K, KAWAI T, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases[J]. Am J Gastroenterol, 2007, 102(2): 302-312. DOI: 10.1111/j.1572-0241.2006.00948.x.
    [24]
    XIONG KG, KE KY, CHEN LF, et al. The relationship between programmed death 1 and inflammatory response in autoimmune hepatitis[J]. Chin J Hepatol, 2017, 25(4): 263-267. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.006.

    熊克宫, 柯坤宇, 陈丽芳, 等. 自身免疫性肝炎患者肝内程序性死亡受体1高表达与肝脏炎症活动相关[J]. 中华肝脏病杂志, 2017, 25(4): 263-267. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.006.
    [25]
    AGINA HA, EHSAN NA, ABD-ELAZIZ TA, et al. Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: Relation to treatment response[J]. Clin Exp Hepatol, 2019, 5(3): 256-264. DOI: 10.5114/ceh.2019.87642.
    [26]
    AARSLEV K, DIGE A, GREISEN SR, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis[J]. Scand J Gastroenterol, 2017, 52(1): 93-99. DOI: 10.1080/00365521.2016.1233576.
    [27]
    MATSUMOTO K, MIYAKE Y, MATSUSHITA H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2014, 29(1): 110-115. DOI: 10.1111/jgh.12340.
    [28]
    BREWER S, NAIR-GILL E, WEI B, et al. Epithelial uptake of[18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice[J]. Gastroenterology, 2010, 138(4): 1266-1275. DOI: 10.1053/j.gastro.2010.01.003.
    [29]
    SALAS JR, CHEN BY, WONG A, et al. (18)F-FAC PET selectively images liver-infiltrating CD4 and CD8 T Cells in a mouse model of autoimmune hepatitis[J]. J Nucl Med, 2018, 59(10): 1616-1623. DOI: 10.2967/jnumed.118.210328.
    [30]
    European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
    [31]
    YANG Q, LIU HE, YOU J, et al. Noninvasive diagnotisc models for chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37(10): 113-117. DOI: 10.3969/j.issn.1001-5256.2021.10.

    杨琴, 刘怀鄂, 游晶, 等. 慢性乙型肝炎肝纤维化的无创诊断模型[J]. 临床肝胆病杂志, 2021, 37(10): 113-117. DOI: 10.3969/j.issn.1001-5256.2021.10.
    [32]
    MAHMUD N, DOSHI SD, FORDE KA, et al. Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis[J]. Clin Exp Hepatol, 2019, 5(3): 244-249. DOI: 10.5114/ceh.2019.87639.
    [33]
    WU S, YANG Z, ZHOU J, et al. Systematic review: Diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis[J]. Hepatol Int, 2019, 13(1): 91-101. DOI: 10.1007/s12072-018-9907-5.
    [34]
    GUO L, ZHENG L, HU L, et al. Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients[J]. Med Sci Monit, 2017, 23: 5106-5112. DOI: 10.12659/msm.907300.
    [35]
    HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68(4): 754-763. DOI: 10.1016/j.jhep.2017.11.020.
    [36]
    JANIK MK, KRUK B, SZCZEPANKIEWICZ B, et al. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis[J]. Liver Int, 2021, 41(2): 348-356. DOI: 10.1111/liv.14726.
    [37]
    LEFEBVRE T, WARTELLE-BLADOU C, WONG P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis[J]. Eur Radiol, 2019, 29(12): 6477-6488. DOI: 10.1007/s00330-019-06331-4.
    [38]
    MENDIZABAL M, MARCIANO S, VIDELA MG, et al. Fulminant presentation of autoimmune hepatitis: Clinical features and early predictors of corticosteroid treatment failure[J]. Eur J Gastroenterol Hepatol, 2015, 27(6): 644-648. DOI: 10.1097/MEG.0000000000000353.
    [39]
    ZIZZO AN, JIMENEZ-RIVERA C, KIM J, et al. A national retrospective study of paediatric end-stage liver disease as a predictor of change to second-line therapy in children with autoimmune hepatitis[J]. Liver Int, 2017, 37(10): 1562-1570. DOI: 10.1111/liv.13387.
    [40]
    BIEWENGA M, INDERSON A, TUSHUIZEN ME, et al. Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis[J]. Liver Transpl, 2020, 26(12): 1573-1581. DOI: 10.1002/lt.25906.
    • Relative Articles

  • Relative Articles

    [1]Yu WANG, Shuang LI, Chenghai LIU. Immunological mechanism of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(12): 2538-2542. doi: 10.12449/JCH241227
    [2]Xueying LIU, Huihui SHI, Haowen WANG, Tao YANG. The material basis and toxic mechanism of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1512-1518. doi: 10.12449/JCH240802
    [3]Yinuo DONG, Yang ZHI, Jieting TANG, Yimin MAO. Diagnosis of herb-induced liver injury： Challenges in practice[J]. Journal of Clinical Hepatology, 2024, 40(8): 1533-1537. doi: 10.12449/JCH240805
    [4]Tingting HE, Zhaofang BAI, Jiabo WANG, Xiaohe XIAO. Phenotypic characteristics and toxicological mechanisms of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1525-1532. doi: 10.12449/JCH240804
    [5]Hui ZHENG, Rong SUN. Influence of combined drug administration on herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1519-1524. doi: 10.12449/JCH240803
    [6]Chenghai LIU. Research advances and challenges in herb-induced liver injury[J]. Journal of Clinical Hepatology, 2024, 40(8): 1505-1511. doi: 10.12449/JCH240801
    [7]Ying LIU, Ping ZHU, Jing LIANG, Huiling XIANG. Value of total bilirubin rebound rate and total bilirubin clearance rate in evaluating the prognosis of severe drug-induced liver injury after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 606-612. doi: 10.3969/j.issn.1001-5256.2023.03.018
    [8]Jinsheng GUO. Prevention and treatment of indirect drug-induced liver toxicity[J]. Journal of Clinical Hepatology, 2022, 38(8): 1923-1926. doi: 10.3969/j.issn.1001-5256.2022.08.040
    [9]Wei YAN, Huifang HUANG. Effect of glucocorticoid in the treatment of severe drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(10): 2302-2307. doi: 10.3969/j.issn.1001-5256.2022.10.019
    [10]Yu WANG, Qiong LUO, Shu LI, Xiaoping SHEN, Shuang LI, Yanyan TAO, Chenghai LIU. A preliminary study on the peripheral seroimmunological characteristics of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2022, 38(5): 1097-1100. doi: 10.3969/j.issn.1001-5256.2022.05.023
    [11]Rongtao LAI, Qing XIE. Clinical features of drug-induced liver failure and related diagnosis and treatment strategies[J]. Journal of Clinical Hepatology, 2021, 37(11): 2534-2538. doi: 10.3969/j.issn.1001-5256.2021.11.006
    [12]Xiaoyun LI, Jieting TANG. Epidemiology of drug-induced liver injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2510-2514. doi: 10.3969/j.issn.1001-5256.2021.11.002
    [13]Shuai CHEN, Changqing YANG. Drug-induced liver injury: Advances and confusions in treatment[J]. Journal of Clinical Hepatology, 2021, 37(11): 2505-2509. doi: 10.3969/j.issn.1001-5256.2021.11.001
    [14]Luo Qiong, Zhu GeRui, Gu HongTu, Liu Kun, Chen GaoFeng, Xing Feng, Tao YanYan, Liu ChengHai. Liver histopathological features of patients with drug-induced liver injury due to Chinese herbal medicine or Western medicine: A comparative analysis of 50 cases[J]. Journal of Clinical Hepatology, 2020, 36(3): 596-601. doi: 10.3969/j.issn.1001-5256.2020.03.025
    [15]Du XiaoFei, Chen Jie, Huang ChunYang, Zhang XiaoDan, Liu Dan, Bian XinQu, Han Ying, Liu YanMin, Dan Jing. Clinical effect and safety of magnesium isoglycyrrhizinate in treatment of autoimmune-like drug-induced liver injury[J]. Journal of Clinical Hepatology, 2020, 36(6): 1330-1333. doi: 10.3969/j.issn.1001-5256.2020.06.028
    [16]Tao LiNa, Qu XiaoYu, Zhang Yue, Song YanQing, Zhang SiXi. Clinical effect of Silybum marianum preparation in the prophylactic treatment of antitubercular agent-induced liver injury: A Meta-analysis of randomized controlled trials[J]. Journal of Clinical Hepatology, 2019, 35(8): 1775-1781. doi: 10.3969/j.issn.1001-5256.2019.08.025
    [17]Chen Jun. Drug-induced liver injury caused by Chinese herbal medicine cannot be neglected[J]. Journal of Clinical Hepatology, 2018, 34(6): 1169-1171. doi: 10.3969/j.issn.1001-5256.2018.06.006
    [18]Liu ChengHai, Zhu ChunWu. Epidemic features, major causes, and diagnostic evaluation of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2017, 33(5): 829-832. doi: 10.3969/j.issn.1001-5256.2017.05.007
    [19]Zhu Yun, Wang RuiLin, Sun XueYing, Yu SiMiao, Jing Jing, Wang JiaBo, He TingTing, Huang YiXue, Wang LiPing, Sun YongQiang. Guiding significance of Guideline for diagnosis and treatment of herb-induced liver injury in clinical diagnosis: a retrospective analysis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2159-2162. doi: 10.3969/j.issn.1001-5256.2016.11.032
    [20]Branch of Hepatobiliary Diseases, China Association of Chinese Medicine, Branch of Chinese Patent Medicine, China Association of Chinese Medicine. Guideline for diagnosis and treatment of herb-induced liver injury[J]. Journal of Clinical Hepatology, 2016, 32(5): 835-843. doi: 10.3969/j.issn.1001-5256.2016.05.003
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (688) PDF downloads(60) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1964]YesterdayPV[4402]TodayIP[2476]TodayPV[5062]Online[69]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return